1-20 of 22
Stephen Fawell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract ND06: First disclosure of AZD8421, a highly selective CDK2 inhibitor to address resistance to CDK4/6 inhibitors in breast and CCNE1-high cancers

Christopher R. Denz, Michael Grondine, Jun Fan, Jessie Hao-Ru Hsu, Anne Jackson, James Robinson, Grace Guo, Wen Li, Yanjun Wang, Maryann San Martin, Laura Prickett, Jeffrey Johannes, Avipsa Ghosh, Kun Song, Dhivya Sudhan, Christina Vasalou, Ryan Richards, Kevin Beaumont, Matthew Peters, Lisa Drew, Stephen Fawell, Frederick W. Goldberg
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): ND06.
https://doi.org/10.1158/1538-7445.AM2024-ND06
Published: 05 April 2024
View article titled, Abstract ND06: First disclosure of AZD8421, a highly selective CDK2 inhibitor to address resistance to CDK4/6 inhibitors in breast and CCNE1-high cancers
Journal Articles

Abstract 4605: AZD4573 in combination with CHOP increases combination benefit in preclinical peripheral T-cell lymphoma models

Danielle Sinead Potter, India Ott, Jamal Saeh, Richard Olsson, Stephen Fawell, Lisa Drew, Justine Roderick
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4605.
https://doi.org/10.1158/1538-7445.AM2024-4605
Published: 22 March 2024
View article titled, Abstract 4605: AZD4573 in combination with CHOP increases combination benefit in preclinical peripheral T-cell lymphoma models
Journal Articles

Abstract 5730: Targeting the cell cycle with AZD8421, a potent and highly selective CDK2 inhibitor

Christopher R. Denz, Michael Grondine, Jun Fan, Jessie Hao-Ru Hsu, Anne Jackson, James Robinson, Grace Guo, Wen Li, Yanjun Wang, Maryann San Martin, Laura Prickett, Jeffrey Johannes, Avipsa Ghosh, Dhivya Sudhan, Christina Vasalou, Ryan Richards, Kevin Beaumont, Matt Peters, Lisa Drew, Stephen Fawell, Frederick W. Goldberg
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5730.
https://doi.org/10.1158/1538-7445.AM2024-5730
Published: 22 March 2024
View article titled, Abstract 5730: Targeting the cell cycle with AZD8421, a potent and highly selective CDK2 inhibitor
Journal Articles

Abstract 3453: First disclosure of a highly potent and selective HPK1 inhibitor that rescues T cell exhaustion

Deanna A. Mele, Neil Grimster, Gayathri Bommakanti, Jason Shields, Lucas Morrill, Kathryn Giblin, Maryann SanMartin, Yanjun Wang, Minwei Ye, Iswarya KarapaReddy, Kun Song, Theresa Proia, Niresh Hariparsad, Ryan Richards, Nadia Luheshi, Simon T. Barry, Stephen Fawell
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3453.
https://doi.org/10.1158/1538-7445.AM2023-3453
Published: 04 April 2023
View article titled, Abstract 3453: First disclosure of a highly potent and selective HPK1 inhibitor that rescues T cell exhaustion
Journal Articles

Abstract 6302: Structure-based and property-based drug design of AZD9574, a CNS penetrant PARP1 selective inhibitor and trapper

Avipsa Ghosh, Sudhir M. Hande, Amber Balazs, Derek Barratt, Sabina Cosulich, Barry Davies, Sébastien Degorce, Kevin Embrey, Sonja Gill, Anders Gunnarsson, Giuditta Illuzzi, Peter Johnström, Jordan Lane, Carrie Larner, Rachel Lawrence, Elisabetta Leo, Andrew Madin, Elizabeth Martin, Lisa McWilliams, Lenka O’Connor, Mark O’Connor, Jonathan Orme, Fiona Pachl, Martin Packer, Andy Pike, Philip Rawlins, Marianne Schimpl, Magnus Schou, Anna Staniszewska, Wenzhan Yang, James Yates, Andrew Zhang, XiaoLa Zheng, Stephen Fawell, Petra Hamerlik, Jeffrey Johannes
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 6302.
https://doi.org/10.1158/1538-7445.AM2022-6302
Published: 15 June 2022
View article titled, Abstract 6302: Structure-based and property-based drug design of AZD9574, a CNS penetrant PARP1 selective inhibitor and trapper
Journal Articles

Abstract 932: Reversing PARP inhibitor resistance by targeting the replication stress response

Mark J. O'Connor, Cristina Cruz, Marta Castroviejo-Bermejo, Urszula M. Polanska, Gemma N. Jones, Anderson Wang, Zhongwu Lai, Josep Forment, Krishna Bulusu, Alba Llop-Guevara, Brian Dougherty, Cristina Saura, Rachel Brough, Chris J. Lord, Alejandra Bruna, Carlos Caldas, Stephen Fawell, J Carl Barrett, Susan E. Critchlow, Judith Balmaña, Elaine Cadogan, Violeta Serra
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 932.
https://doi.org/10.1158/1538-7445.AM2019-932
Published: 01 July 2019
View article titled, Abstract 932: Reversing PARP inhibitor resistance by targeting the replication stress response
Journal Articles

Abstract LB-192: The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression of CD103+ dendritic cells

Christine M. Barbon, Alexandra Borodovsky, Yanjun Wang, Laura Prickett, Kris Sachsenmeier, Alwin Schuller, Wenlin Shao, Carl Barrett, Stephen Fawell, Deanna A. Mele
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): LB-192.
https://doi.org/10.1158/1538-7445.AM2019-LB-192
Published: 01 July 2019
View article titled, Abstract LB-192: The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression of CD103+ dendritic cells
Journal Articles

Abstract 1026: Identify BRD4 as a facilitator of replication stress response signaling

Jingwen Zhang, Brandon Willis, Maureen Hattersley, Alan Lau, Corinne Reimer, Michael Zinda, Stephen Fawell, Gordon Mills, Austin Dulak, Huawei Chen
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 1026.
https://doi.org/10.1158/1538-7445.AM2017-1026
Published: 01 July 2017
View article titled, Abstract 1026: Identify BRD4 as a facilitator of replication stress response signaling
Journal Articles

Abstract 3168: Your targeted population might not be what you predict: Changes in tumor genetic landscapes post standard of care

Danielle Greenawalt, Austin Dulak, Manasa Ramakrishna, Zhongwu Lai, Justin Johnson, Hongyue Dai, Melissa Mitchell, Carl Barrett, Stephen Fawell, Jonathan Dry
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 3168.
https://doi.org/10.1158/1538-7445.AM2016-3168
Published: 15 July 2016
View article titled, Abstract 3168: Your targeted population might not be what you predict: Changes in tumor genetic landscapes post standard of care
Journal Articles

Abstract 1971: BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer

Garrett W. Rhyasen, Yi Yao, Austin Dulak, Lillian Castriotta, Kelly Jacques, Maureen Hattersley, Gordon B. Mills, Michael Zinda, Stephen Fawell, Paul Lyne, Edwin Clark, Huawei Chen
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 1971.
https://doi.org/10.1158/1538-7445.AM2016-1971
Published: 15 July 2016
View article titled, Abstract 1971: BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer
Journal Articles

Abstract 1706: Whole exome sequencing of pre and post treatment diffuse large B cell lymphoma reveals the mutation spectrum of the relapse/refractory patient population

Danielle Greenawalt, Kate Byth, Zhongwu Lai, Justin Johnson, Ambar Ahmed, Brian Dougherty, Kenneth Thress, Michael Zinda, Winnie S. Liang, John Carpten, Stephen Fawell, J. Carl Barrett
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 1706.
https://doi.org/10.1158/1538-7445.AM2015-1706
Published: 01 August 2015
View article titled, Abstract 1706: Whole exome sequencing of pre and post treatment diffuse large B cell lymphoma reveals the mutation spectrum of the relapse/refractory patient population
Journal Articles

Abstract 1477: Pharmacodynamic response and anti-tumor activity of the MET inhibitor AZD6094 in papillary renal cell carcinoma patient derived xenograft models

Alwin Schuller, Evan Barry, Rhys Jones, Melanie Frigault, Garry Beran, Ryan Henry, David Linsenmayer, Maureen Hattersley, Aaron Smith, Joanne Wilson, Ammar Adam, Michael Zinda, Corinne Reimer, Stephen Fawell, Edwin Clark, Celina D'Cruz
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 1477.
https://doi.org/10.1158/1538-7445.AM2015-1477
Published: 01 August 2015
View article titled, Abstract 1477: Pharmacodynamic response and anti-tumor activity of the MET inhibitor AZD6094 in papillary renal cell carcinoma patient derived xenograft models
Journal Articles

Abstract 761: Changing the paradigm for treating drug resistance in NSCLC: Novel combinations of AZD6094, a selective MET inhibitor, and an irreversible, selective (EGFRm/T790M) EGFRTKI, AZD9291

Celina D'Cruz, Evan Barry, Ryan Henry, Lillian Castriotta, Alwin Schuller, Garry Beran, Susan Ashton, Cath Eberlein, Corinne Reimer, Melanie Frigault, Michael Zinda, Darren Cross, Stephen Fawell
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 761.
https://doi.org/10.1158/1538-7445.AM2015-761
Published: 01 August 2015
View article titled, Abstract 761: Changing the paradigm for treating drug resistance in NSCLC: Novel combinations of AZD6094, a selective MET inhibitor, and an irreversible, selective (EGFRm/T790M) EGFRTKI, AZD9291
Journal Articles

Abstract 3063: Mcl-1 dependency is a predictive biomarker for apoptotic induction by short-term dinaciclib (SCH 727965) treatment

Robert Booher, Heather Hirsch, Peter Strack, Leigh Zawel, Stephen Fawell
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 3063.
https://doi.org/10.1158/1538-7445.AM2012-3063
Published: 15 April 2012
View article titled, Abstract 3063: Mcl-1 dependency is a predictive biomarker for apoptotic induction by short-term dinaciclib (SCH 727965) treatment
Journal Articles

Abstract 4931: Biomarker discovery in a large panel of cell lines shows different sample size requirement for prediction of response across a set of compounds

Michael Nebozhyn, Razvan Cristescu, Yaping Liu, Igor Feldman, Sergey Lezhnin, Theresa Zhang, Leigh Zawel, Stephen Fawell, Hongyue Dai, Jing Li, Andrey Loboda
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 4931.
https://doi.org/10.1158/1538-7445.AM2012-4931
Published: 15 April 2012
View article titled, Abstract 4931: Biomarker discovery in a large panel of cell lines shows different sample size requirement for prediction of response across a set of compounds
Journal Articles

Abstract 3853: TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches

Heather Huet, Alwin Schuller, Jing Li, Jennifer Johnson, Bruno Dombrecht, Kris Meerschaert, Karen Cromie, Sanela Bilic, Sharon Li, Andrew Garner, Sandra Nunes, Rajiv Chopra, Kirk Clark, Megan Yao, Stephen Fawell, David Stover, William R. Sellers, Seth Ettenberg
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 3853.
https://doi.org/10.1158/1538-7445.AM2012-3853
Published: 15 April 2012
View article titled, Abstract 3853: TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches
Journal Articles

Abstract 138: Therapeutic targeting of inhibitor of apoptosis proteins

Leigh S. Zawel, Christopher Straub, Brant Firestone, John Sullivan, Kymberly Levine, Dale Porter, Colleen Conway, Guizhi Yang, Hui Gao, Dan He, Joanna Slisz, Michael Morrissey, John Monahan, Rebecca Mosher, Frank Stegmeier, Feng He, Ly Pham, Fan Yang, Julian Chen, Tim Ramsey, Megan Yao, Stephen Fawell
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 138.
https://doi.org/10.1158/1538-7445.AM10-138
Published: 15 April 2010
View article titled, Abstract 138: Therapeutic targeting of inhibitor of apoptosis proteins
Journal Articles

Mechanism of action studies using a Smac mimetic reveal positive and negative roles of inhibitor of apoptosis proteins (IAPs) in TNFα signaling

Leigh Zawel, Alex Gaither, Dale Porter, Yao Yao, Christopher Straub, Tim Ramsey, Vadim Iourgenko, Huang Alan, Robert Schlegel, Mark Labow, Stephen Fawell, William Sellers
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): SY26-04.
Published: 01 May 2008
View article titled, Mechanism of action studies using a Smac mimetic reveal positive and negative roles of inhibitor of apoptosis proteins (IAPs) in TNFα signaling
Journal Articles

Potent anticancer activity of a pan-deacetylase inhibitor panobinostat (LBH589) as a single agent in in vitro and in vivo tumor models

Wenlin Shao, Joseph Growney, Yun Feng, Ping Wang, Yan Yan-Neale, Gregory O'Connor, Paul Kwon, Yung-mae Yao, Stephen Fawell, Peter Atadja
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 735.
Published: 01 May 2008
View article titled, Potent anticancer activity of a pan-deacetylase inhibitor panobinostat (LBH589) as a single agent in <em>in vitro</em> and <em>in vivo</em> tumor models
Journal Articles

Potent anticancer activity of the deacetylase inhibitor panobinostat (LBH589) in colon cancer cell lines and patient-derived primary colon cancer xenografts

Youzhen Wang, Joseph Growney, Jane Cheng, Colleen Kowal, Guizhi Yang, Rebecca Mosher, Ronald Meyer, Yan Yan-Neale, Minying Pu, Wenlin Shao, Yun Feng, Paul Kwon, Peter Atadja, Stephen Fawell, Yung-mae Yao
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 2442.
Published: 01 May 2008
View article titled, Potent anticancer activity of the deacetylase inhibitor panobinostat (LBH589) in colon cancer cell lines and patient-derived primary colon cancer xenografts